immunotherapeutic approaches for mcl patients who progress following btki treatment
Published 9 months ago • 43 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
3:11
immunotherapeutic options for patients with mcl who progress on btk inhibitors
-
2:48
selecting between btk inhibitors in mcl & addressing resistance to these agents
-
1:52
the sequencing of therapies for r/r mcl: btkis and novel agents
-
1:15
the role of btk inhibitors in the frontline treatment of mcl
-
2:09
the optimal sequencing of novel therapies in mantle cell lymphoma
-
4:00
immunotherapies for the treatment of high-risk mm
-
6:56
emerging therapies in mcl: the promise of immunotherapies
-
1:10
an update on novel treatments for mcl
-
5:15
the promise of immunotherapies in t-cell lymphoma
-
3:40
master class in transplantation and hematology: highlights
-
1:32
promising novel immunotherapeutic approaches in lymphoma
-
1:43
updates on the use of bispecific antibodies in mcl & the need for more studies in this space
-
1:18
the role of cellular immunotherapies in the future treatment of hl
-
2:12
social media – a useful tool for hematological research
-
1:53
preclinical research for the future of cellular therapies
-
3:51
novel agents in mzl: btkis, pi3k inhibitors, and immunotherapeutics
-
1:38
advice for community physicians on the management of mantle cell lymphoma
-
3:47
the role of immunotherapy in the aml treatment landscape
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll